SSIISS Innovations International, Inc.
Is the business good?
Margins widening. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is SSII?
SS Innovations International, Inc. earns −17% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
Return on invested capital · cost of capital 9.0% · 26 points below what the capital costs: growth destroys value
- Operating margin
- −16%
Operating margin · Medical Devices median 2.1% · 12 months to Q2 2026
- Share count, year on year
- +3.3%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 11%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2022 | −206% |
| FY2023 | −345% |
| FY2024 | −92% |
| FY2025 | −19% |
Details›
- Gross margin12 months to Q2 2026
- 48%
- Operating margin12 months to Q2 2026
- −16%
- Net margin12 months to Q2 2026
- −24%
- Free cash flow margin
- −35%
- R&D as % of revenue
- 11%
- Revenue, trailing twelve months
- $52M
- Free cash flow, trailing twelve months
- −$18M
- Net income, trailing twelve months
- −$12M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −17%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.